secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193805-24-000022
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8
--------------------------------------------------------------------------------

- First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.
- Second tranche mandatory $80M at $1.716/share conditional on Phase 2b topline data for vidofludimus calcium in PMS (April 2025) and stock price/volume thresholds.
- Third tranche up to $80M at same price but cashless settlement possible; total gross proceeds $80M–$240M.
- Proceeds to fund vidofludimus calcium, IMU-856, and IMU-381 clinical development; first tranche extends cash runway into Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/0001193805-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer